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Abstract A substantial volume of the consultations
requested of gastroenterologists are directed towards the
evaluation of anemia. Since iron deﬁciency anemia often
arises from bleeding gastrointestinal lesions, many of
which are malignant, establishment of a ﬁrm diagnosis
usually obligates an endoscopic evaluation. Although the
laboratory tests used to make the diagnosis have not
changed in many decades, their interpretation has, and this
is possibly due to the availability of extensive testing in key
populations. We provide data supporting the use of the
serum ferritin as the sole useful measure of iron stores,
setting the lower limit at 100 lg/l for some populations in
order to increase the sensitivity of the test. Trends of the
commonly obtained red cell indices, mean corpuscular
volume, and the red cell distribution width can provide
valuable diagnostic information. Once the diagnosis is
established, upper and lower gastrointestinal endoscopy
is usually indicated. Nevertheless, in many cases a
gastrointestinal source is not found after routine evaluation.
Additional studies, including repeat upper and lower
endoscopy and often investigation of the small intestine
may thus be required. Although oral iron is inexpensive
and usually effective, there are many gastrointestinal con-
ditions that warrant treatment of iron deﬁciency with
intravenous iron.
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Introduction
Evaluation of anemia has traditionally been performed by
primary care physicians, internists, and hematological
specialists. Yet many practitioners now regard colonoscopy
as an essential component of the anemia evaluation, to the
extent that many anemia consultations are directed to
gastroenterologists, often offering no more information
than a complete blood count, and requesting that the spe-
cialist ‘‘rule out cancer,’’ ‘‘diagnose anemia,’’ or more
typically, ‘‘perform colonoscopy.’’ The recent shift of the
burden of diagnosing and treating anemia to gastroente-
rologists, coupled with recent changes in the interpretation
of traditional diagnostic testing, prompted us to review this
topic with the purpose of providing gastroenterologists
with an approach that should prove helpful in clinical
practice. In this review, we will provide basic information
about the pathogenesis, diagnosis, and treatment of iron
deﬁciency anemia (IDA), a type of anemia of interest to
gastroenterologists due to its prevalent gastrointestinal
etiology and its need for endoscopic evaluation. Although
this review is necessarily focused on the pathogenesis,
etiology, diagnosis, and treatment of IDA, and not other
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DOI 10.1007/s10620-009-1108-6causes of anemia, recognition that anemia is not due to
IDA can provide valuable information for the referring
practitioner. We will provide data supporting a uniform and
organized approach to the diagnosis and treatment of IDA
in a likely referral population that can easily be undertaken
by gastrointestinal specialists. Please note that the intent of
this review is not a thorough or exhaustive coverage of
IDA; in particular, speciﬁc populations, such as those
receiving hemodialysis will not be discussed. The reader is
also referred to a recent review addressing iron deﬁciency
in digestive diseases [1].
Iron Deﬁciency Anemia
Iron deﬁciency anemia (IDA) affects approximately 30%
of the world’s population [2]. Although more prevalent in
children and neonates, IDA remains extremely common in
the adult population. In the United States, 5–12% of non-
pregnant women and 1–5% of men have IDA [3]. The
prevalence varies greatly according to age, gender, race,
and ethnicity (Table 1). In premenopausal women, men-
strual blood loss and pregnancy-related iron losses account
for most IDA diagnoses. Nevertheless, occult bleeding
from the gastrointestinal (GI) tract is the leading cause for
IDA in men and postmenopausal women. A loss of 10 ml
of blood per day is usually required for a positive guaiac-
based fecal occult blood test (FOBT), although FOBT
positivity is highly dependent on the locus of the bleeding
source [4]. Bleeding lesions in the GI tract are identiﬁed in
about 50% of patients with IDA [5]. GI malignancy is also
signiﬁcantly more common in men and postmenopausal
women with IDA, with a prevalence of 10–17% [6, 7].
Factors such as older age, male sex, elevated serum lactate
dehydrogenase (LDH), and lower ferritin are considered
markers for GI malignancy in IDA patients [7, 8]. Pre-
dictive factors for IDA in patients with colorectal cancer
include female gender, right-sided tumors, and a tumor
diameter[3c m[ 9].
About one-third of the patients with inﬂammatory bowel
disease (IBD) are anemic[2]. Although anemia in IBD often
involves a combination of IDA and the anemia of chronic
disease (ACD), IDA remains an important contributor via:
(1) decreased iron intake due to avoidance of foods that may
exacerbate symptoms of IBD; (2) chronic intestinal bleed-
ing; (3) impaired iron absorption in Crohn’s disease of the
duodenum or upper jejunum; and (4) increased erythropoi-
etin response that cannot be matched to the available iron,
resulting in ineffective erythropoiesis [2].
Therefore, an evaluation of the GI tract should be part of
a thorough diagnostic assessment in adults with IDA.
Although particular attention should be given to adult men
and postmenopausal women [4], premenopausal women
and young patients with IDA may also provide unique
diagnostic challenges.
Iron Absorption and Metabolism
Gastrointestinal Iron Absorption
Dietary iron consists of about 5–15 mg of elemental iron
and 1–5 mg of heme iron, of which about 1–2 mg is
intestinally absorbed. Children, adult males, and post-
menopausal women require 10 mg of elemental iron daily.
In premenopausal and pregnant women, the requirement
increases by two to three fold [10]. The mechanism of
heme iron absorption is unknown. Inorganic iron may be
absorbed via the divalent metal transporter-1 (DMT-1), a
protein that transports a number of divalent metals,
including ferrous iron (Fe
2?). Nevertheless, dietary iron in
the duodenum, particularly from plant sources is likely
ferric iron (Fe
3?); therefore a membrane cytochrome
containing ferrireductase is necessary to reduce (Fe[III]) to
(Fe[II]). DMT-1 is principally expressed in the enterocyte
cytoplasm and lamina propria, but is also expressed in
goblet cells and in the overlying mucous layer [11]. DMT-1
is inserted into the brush border membrane with overall
increased expression in IDA; inorganic iron is also taken
up by the integrin-mobilferrin-paraferritin (IMP) pathway.
Once transported across the duodenal luminal membrane,
iron is carried across the cytoplasm by a carrier protein and
is bound by transferrin at the basolateral membrane. Iron is
Table 1 Prevalence of IDA in the United States (adapted from the
Centers for Disease Control and Prevention)
Group/age 1988–1994 (%) 1999–2000 (%)
Children
1–2 9 7
3–5 3 5
6–11 2 4
Women (non-pregnant)
12–49 11 12
50–69 5 9
70 7 6
Men
12–15 1 5
16–69 1 2
70 4 3
Women by racial/ethnic group
Non-Hispanic white 8 10
Black 15 19
Mexican living in U.S. 19 22
Iron deﬁciency—United States, 1999–2000. MMWR Morb Mortal
Wkly Rep. 2002;51:897–899
Dig Dis Sci (2010) 55:548–559 549
123released from the intestinal mucosa via hephaestin, a
ceruloplasmin-like ferro-oxidase, and ferroportin, another
transport protein [12]. Both DMT-1 and ferroportin are
regulated by the hepatically secreted defensin hepcidin,
which impairs transduodenal iron transport (see below).
Sources of Iron Loss
GI Blood Loss
Under usual circumstances, in the absence of occult
bleeding, the predominant source of iron loss is in the iron-
containing cytochromes of sloughed epithelial cells, which
account for a loss of *1 mg/day. GI tract microerosions
and other forms of occult blood loss can account for
1–2 mg of iron loss daily. In the plasma, iron is usually
bound by transferrin and is taken up by tissues expressing
cell-surface transferrin receptors. Circulating iron is mostly
taken up by the bone marrow in order to generate hemo-
globin for red blood cells, whereas 10–15% is taken up by
muscle ﬁbers to generate myoglobin. After a half-life of
120 days, senescent RBCs are engulfed by reticuloendo-
thelial macrophages; iron is recycled into the plasma for
redistribution to other tissues via transferrin. Intracellu-
larly, iron is stored as ferritin, particularly in the hepatic
reticuloendothelial macrophages and in hepatocytes. Fer-
ritin is measurable in plasma, where it correlates closely
with bone marrow stores in the steady state [13, 14]. Fer-
ritin is elevated in inﬂammatory disease states since it is an
acute-phase reactant [15–17]. There are also a number of
iron responsive element binding proteins that regulate the
balance of iron. Hepcidin inhibits the release of iron into
the plasma from enterocytes, hepatocytes, and macro-
phages when the plasma level of iron is increased [18].
Iron Malabsorption or Deﬁcient Diet
In rare situations, IDA can occur in the absence of chronic
GI blood loss. Celiac disease, although mostly associated
with diarrhea and malabsorption, can also manifest extra-
intestinal symptoms such as dermatitis, arthritis, and
immunologic problems. In one study, IDA was the clinical
presentation of 28% of subjects with ‘‘silent’’ (only extra-
intestinal symptoms) celiac disease [19], presumably due to
duodenal involvement with iron malabsorption. Hypo-
chlorhydric states, such as atrophic gastritis due to chronic
infection with Helicobacter pylori or autoimmune gastritis,
or in rare cases, chronic, high-dose therapy with proton
pump inhibitors have been implicated in the pathogenesis
of IDA [20–24]. Since the duodenum is the major locus of
iron absorption, surgical duodenal bypass, formerly for
peptic ulcer disease, and more recently as part of gastric
bypass for obesity, have also been associated with the
development of IDA [25, 26]. An acute loss of 4 units or
more (2 l) of blood can deplete iron stores. Lastly, the
consumption of an iron-deﬁcient diet, such as occurs in
strict vegans, can deplete iron stores if the diet is adhered to
for three or more years in the absence of excessive losses
[10].
Non-GI Sources of Chronic Occult Blood Loss
Although it is possible to lose blood from the airway and
urinary system, the loss is seldom occult, and thus comes to
medical attention prior to the development of IDA. An
exception can be tumors or lesions of the urothelium,
which can bleed occultly prior to producing symptoms, or
more rarely, chronic intravascular hemolysis, in which
hemoglobin is released from damaged red cells into the
plasma, where it is excreted in the urine, detectable as
hemosiderin in the urine sediment.
Signs and Symptoms
Patients with mild IDA are most likely asymptomatic.
When the anemia becomes more severe, patients may
present with nonspeciﬁc symptoms such as fatigue, pallor,
and dyspnea on exertion. Physical examination may reveal
tachycardia, generalized and conjunctival pallor, koilo-
nychia, glossitis, stomatitis, and ﬁndings consistent with
heart failure. Behavioral changes such as pica (the craving
and consumption of nonfood items) and restless leg syn-
drome may also be present [27, 28]. Patients with GI
causes of IDA may occasionally complain of ‘‘alarm’’
symptoms such as a change in stool caliber, epigastric pain,
and change in bowel habits, weight loss, early satiety, and
poor appetite. Esophageal webs associated with IDA
comprise the Plummer–Vinson syndrome.
Laboratory Diagnosis
Red Cell Indices, Serum Iron, and Iron Binding Capacity
Iron deﬁciency is usually diagnosed with laboratory tests.
Low serum hemoglobin in the setting of a reduced mean
corpuscular volume (MCV) isusually the initial ﬁnding on a
routine complete blood count. Red cell distribution width
(RDW) has been proposed as a sensitive indicator for IDA.
Increased RDW represents heterogeneity in the red blood
cellvolumedistribution,equivalenttoanisocytosisobserved
in a peripheral blood smear. A signiﬁcant increase in mean
RDW can be used to diagnose IDA (sensitivity 81.0%,
speciﬁcity 53.4%) [29]. An inverse relationship is also
observed between the serum hemoglobin and the RDW in
IDA [29]. Although the absolute values of red cell indices
550 Dig Dis Sci (2010) 55:548–559
123may vary and be confounded by coincident diseases such as
heterozygousthalassemiasyndromes,thetrendofRDWand
MCV over time can be quite instructive [3]. Iron deﬁciency
usually initially manifests as a falling MCV accompanied
by a rising RDW, due to the increasing preponderance of
microcytes in the circulation [30–32]. With iron treatment,
the marked reticulocytosis occurring in the ﬁrst 4 weeks
following therapy is manifest as a sudden increase of
RDW, sometimes toover 30% [33].Thus apatternof falling
MCV accompanied by a rising RDW should alert the clini-
cian to the presence of possible IDA. The marked RDW
increase occurring after the initiation of therapy helps con-
ﬁrm the diagnosis (Fig. 1).
Additional laboratory ﬁndings in IDA include elevated
total iron-binding capacity (TIBC), low transferrin satura-
tion, and low serum iron level. Due to the large overlap
of transferrin saturation among subjects with IDA, ACD,
and those with a mixed diagnosis, the use of transferrin
saturation in the diagnosis of IDA has been discouraged
[15, 34].
Serum Ferritin
Serum ferritin is the single best laboratory test for the
diagnosis of iron deﬁciency. In patients with bleeding
colorectal adenomas C1 cm, serum ferritin may decrease
before a decrease in the serum iron level is detected [35].
Every 1 lg/l of serum ferritin corresponds to 8–10 mg
storage of iron [13]. Based on a review of multiple clinical
trials where the diagnosis of IDA was conﬁrmed by bone
marrow aspiration or a positive response to exogenous iron
administration, Guyatt et al. [15] calculated that the pre-
dictive value or area under the receiver operating charac-
teristic (ROC) curve for serum ferritin is 0.95 (p\0.001),
compared to 0.77 for MCV, 0.74 for transferrin saturation,
and 0.62 for absolute RDW. The likelihood ratio (LR),
which incorporates sensitivity and speciﬁcity into calcu-
lating how much the odds of the disease increase when a
test is positive, provides a convenient means of ascribing
probability of disease according to a laboratory value
(Table 2)[ 15]. Kis et al. [34] in a retrospective study of
101 veterans who had undergone bone marrow aspirations,
also found that the ROC for ferritin was superior to TIBC
or to transferrin saturation, calculating that a ferritin
of B100 lg/l had a 64.9% sensitivity and a 96.1% speci-
ﬁcity for IDA. In another study, Sawhney et al. [36]
reported that a threshold of 100 lg/l effectively stratiﬁed
anemic veterans into a high-risk group for advanced neo-
plasia from a low-risk non-anemic group. Based on these
data, a simple clinical cutoff can guide management of
anemic subjects: serum ferritin\15 lg/l rules in iron
deﬁciency, serum ferritin[100 lg/l mostly excludes iron
deﬁciency; intermediate values warrant further investiga-
tion [15]. Although ferritin level increases with age, and is
an acute-phase reactant that may be falsely elevated in the
setting of chronic inﬂammation, infection, malignancy and
chronic renal failure, the sensitivity and speciﬁcity of the
serum ferritin is little changed if the 100 lg/l threshold is
used [15, 34]. Thus, a lower limit of normal of 100 lg/l for
ferritin might serve as a simple diagnostic test to effec-
tively stratify patients for endoscopic evaluation, including
subjects that might have been uninvestigated according to
more stringent thresholds. Although this higher range will
lead to the investigation of more false-positives, most
subjects will be over 50 years old in any case and thus
eligible for screening colonoscopy, perhaps justifying the
excess risk.
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Fig. 1 Red cell indices and Hgb over time in a patient with severe
iron deﬁciency anemia prior to and after successful treatment. Note
the fall of MCV accompanied by a rise of RDW as the deﬁciency
progressed, with marked increase of RDW immediately following the
institution of therapy
Table 2 Likelihood ratios (LR) and conﬁdence interval (CI) for the
presence of IDA stratiﬁed by serum ferritin (adapted from [15])
Serum ferritin LR 95% CI
C100 lg/l 0.08 0.07–0.09
45\100 lg/l 0.54 0.48–0.60
35\45 lg/l 1.83 1.47–2.19
25\35 lg/l 2.54 2.11–2.97
15\25 lg/l 8.83 7.22–10.44
B15 lg/l 51.85 41.53–62.27
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123Investigational Tests
Several other indices of iron deﬁciency have been under
investigation. The following are a few highlights from
recent studies.
Serum Transferrin Receptors
Similar to serum ferritin, serum transferrin receptors
(sTFR) may be used to estimate body iron stores [3]. sTFR
is a transmembrane glycoprotein that transfers circulating
iron into RBCs. In IDA, sTFR is expressed on erythrocyte
membranes, enabling the detection of the receptor soluble
extracellular domain in the circulation. sTFR is dependent
on erythroid precursors in the bone marrow and on the
number of sTFRs per cell. Although the sTFR is sensitive
and is not affected by inﬂammation, it is not widely
available. Furthermore, the assay is not standardized,
which impedes its clinical application [17, 37].
Erythrocyte Zinc Protoporphyrin
The erythrocyte zinc protoporphyrin assay (ZnPP) is
another laboratory screening method used to assess iron
status. In IDA, DMT-1 is upregulated, which increases zinc
transport across the intestinal membrane to replace the
missing iron in the formation of the protoporphyrin ring
[38]. ZnPP assay is a sensitive test, but speciﬁcity may be
limited because ZnPP increases in the settings of inﬂam-
mation, lead poisoning, ACD, and hemoglobinopathies
[37].
Reticulocyte Hemoglobin Content
The reticulocyte hemoglobin content (CHr) reﬂects the
amount of iron available to the bone marrow for incor-
poration into new RBCs since reticulocytes are only
1–2 days old. The sensitivity and speciﬁcity of this test
are comparable to those of serum ferritin [17]. Based on
the same concept, another marker of iron status is the
percentage of hypochromic RBC’s (PHRC). PHRC tests
the concentration of hemoglobin in RBCs rather than the
hemoglobin content, as in CHr. Nevertheless, the test’s
utility is in question since PHRC is dependent on the size
of the RBCs, which may vary with the length of storage
time, and therefore cannot be shipped to off-site labora-
tories [17]. These tests are particularly useful in the
diagnosis of iron deﬁciency in the presence of inﬂam-
mation and ACD [39].
When the diagnosis remains ambiguous after laboratory
results are analyzed, a bone marrow biopsy should be
considered in order to make a deﬁnitive diagnosis. The
absence of stainable iron is the ‘gold standard’ for diag-
nosis of IDA.
Further Testing for Anemia Other Than IDA
In addition to IDA, other causes of microcytic, hypochro-
mic anemia to consider are thalassemias, ACD, and side-
roblastic anemia. Evaluation for thalassemia or other
hemaglobinopathies should be considered in those with a
family history or are from high-risk populations, particu-
larly with origins from the Mediterranean basin or South-
east Asia [40]. In comparison, red blood cell production is
usually low in IDA, but normal to high in thalassemias.
Sideroblastic anemia is diagnosed by visualizing ringed
sideroblasts in Prussian blue-stained bone marrow.
Gastrointestinal Evaluation
FOBT
An FOBT is routinely used in detecting blood loss from the
GI tract. As mentioned earlier, a loss of 10 ml/day is
usually required for the majority of FOBT to become
positive; 30 ml/day was associated with 93% positivity
[41]. The routine use of FOBT for diagnosing IDA, how-
ever, can be questioned due to the markedly poor ROC of
the test [42, 43]. Nevertheless, FOBT may be useful for
risk-stratifying premenopausal subjects with IDA (see
below). In general, IDA should be diagnosed by serum
ferritin studies combined with the trend of the red cell
indices. Using tests of stool hemoglobin in the diagnosis of
IDA is discouraged in subjects aged[50 years as the tests,
whether negative or positive, are unlikely to change the
need for endoscopic or other evaluation of the GI tract.
GI Tract Evaluation
Lower and upper GI tract evaluation is recommended to
diagnose the cause of IDA, particularly in men C50 and in
post-menopausal women, in whom IDA is suspected to
occur from a bleeding lesion.
Premenopausal Women
Since premenopausal women comprise the largest category
of IDA subjects, the gastroenterologist frequently encoun-
ters constituents from this group with suspected gastroin-
testinal blood loss. Since physiological blood loss is greater
in this group than any other, and since there are relatively
few controlled studies investigating the etiology of
IDA in this population, the indications for gastrointestinal
552 Dig Dis Sci (2010) 55:548–559
123evaluation can be problematic. Although IDA in most
premenopausal women can be attributed to menstrual
blood loss and insufﬁcient dietary intake [3], a substantial
portion harbor signiﬁcant underlying gastrointestinal tract
lesions, particularly of the upper tract [44–46]. The aver-
age age of menopause is 51 years, and since premeno-
pausal patients with IDA near or even surpass this age,
their risk for colorectal malignancy increases accordingly.
If menstrual blood loss is signiﬁcant and appears to be the
primary source of IDA, then gynecologic evaluation and
management should be priority. Gastrointestinal tract
evaluation should be pursued in those who have anemia
that is severe or remains refractory to iron treatment, have
signiﬁcant gastrointestinal symptoms, weight loss, positive
fecal occult blood testing, are[40 years of age, or those
whose menstrual blood loss does not correlate with the
severity of their IDA [45, 46]. Green and Rockey reported
that in 111 women referred to GI specialists for IDA, use
of aspirin (ASA) or nonsteroidal anti-inﬂammatory drugs
(NSAIDs) and upper GI symptoms were associated with
upper lesions whereas weight loss C 10 lb., FOBT posi-
tivity and lower GI symptoms were more associated with
lower lesions. In a study of 186 premenopausal women
referred for gastroenterological evaluation, Hgb\10,
FOBT positivity, abdominal symptoms, and weight
loss C5 kg were predictive of the presence of gastroin-
testinal lesions. The authors reported ﬁnding ﬁve gastric
and six colon cancers in this referral group but no intestinal
lesions were identiﬁed with conventional small intestinal
radiography performed on the 166 subjects in which no
upper or lower lesion was identiﬁed [46]. In a study of 166
pre-menopausal women referred for gastrointestinal eval-
uation, the symptoms of heartburn and regurgitation,
Hgb\10, and MCV\72 were signiﬁcant positive pre-
dictors for signiﬁcant GI lesions, whereas a history of
meno-metrorrhagia was a signiﬁcant negative predictor. Of
the 35 women with GI lesions, 47% were diagnosed with
H. pylori (Hp) gastritis and 17% with celiac disease, with
the authors recommending routine use of the urea breath
test and celiac serologies in their population, with endo-
scopic evaluation reserved only for those who test negative
for Hp or celiac disease or whose IDA fails to resolve after
Hp eradication [47]. Nevertheless, an upper endoscopy
should be considered in those with predictive symptoms, or
with suspected Hp gastritis or celiac disease so that con-
ﬁrmatory histology can be obtained and other lesions
excluded.
Due to the relatively few studies published about the
gastrointestinal etiology of IDA in the pre-menopausal
population, combined with a study design that for most is
heavily biased towards a referral population, guidelines
based on grade A evidence regarding the gastrointestinal
evaluation of this population are lacking. Nevertheless,
agreement among the published studies is sufﬁcient to
guide clinical decision-making, with the main principle
that GI lesions are frequent and malignancies are present in
this population; the threshold for endoscopic investigation
should thus be low.
Types of Tests Available
GI evaluation can be endoscopic and radiographic. Endo-
scopic tests include esophagogastroduodenoscopy (EGD),
colonoscopy, enteroscopy, and wireless capsule endoscopy
(WCE), whereas radiographic tests include barium enema,
upper GI series with or without small-bowel follow-
through, enteroclysis, abdominal computer tomography
(CT), and CT colonography. The choice of study is largely
dependent on the clinician’s experience, test availability,
the patient’s comorbidities, and the type and location of the
suspected lesion.
GI Tract Lesions
Although IDA has historically been associated with lesions
in the colon, upper GI tract lesions are also commonly
found in patients with IDA [4, 48]. Cancer is the most
common lesion found in the colon, whereas peptic ulcer is
the most common lesion identiﬁed in the upper GI tract
[48]. A list of the upper and lower GI bleeding conditions
associated with IDA is included in Table 3. As previously
discussed, the existence of non-bleeding sources of IDA,
including celiac disease, prior gastric surgery, and chronic
atrophic gastritis from Hp infection or autoimmune gas-
tritis can compromise iron absorption. Therefore, upper
endoscopic evaluation should include random gastric antral
and fundic biopsies in addition to duodenal biopsies in
order to assess the histological changes of atrophic gastritis
and celiac disease [49]. Celiac disease must be considered
as a cause for IDA particularly in the younger population,
in particular populations with Northern European ancestry,
and as previously noted can present with or without overt
GI symptoms [50]. Some authors advocate serologic and
biochemical screening when clinical suspicion for celiac
disease and atrophic gastritis is high or in otherwise
unexplained IDA, especially in light of a reported preva-
lence of celiac disease in IDA of 3–15% and atrophic
gastritis of 20–27% [20, 21, 50, 51]. GI investigation in
elderly patients with iron deﬁciency or depletion, irre-
spective of hemoglobin level, is recommended since a
similar prevalence of GI lesions was observed in iron-
depleted or deﬁcient patients without anemia as in those
with anemia [52]. Conversely, the likelihood of bleeding
GI lesions is low in anemic patients without iron deﬁ-
ciency. These patients should probably not undergo diag-
nostic investigation of the GI tract for this indication [5],
Dig Dis Sci (2010) 55:548–559 553
123although as discussed above, the risk of cancer or of
advanced neoplasia may be higher in anemic subjects with
ferritin[30 and\100 lg/l [36].
Obscure Lesions
About 5–10% of patients with anemia from suspected
gastrointestinal origin have no source found after EGD and
colonoscopy are performed [53]. A possible explanation to
consider is a missed lesion, since up to 25% of patients
with initially negative studies have upper tract lesions
when EGD is repeated. Some unusual and difﬁcult-to-
recognize lesions in the upper tract include Cameron
lesions in hiatal hernias, watermelon stomach, portal
hypertensive gastropathy, and vascular ectasias. Important
lesions can also be missed with colonoscopy, particularly
when bowel preparation is poor for the initial exam [4].
Moreover, a small-bowel lesion is detected in approxi-
mately 75% of patients with a negative EGD and colon-
oscopy after further investigation [54]. As recommended
by the American Gastroenterological Association (AGA),
patients who have persistent or recurrent IDA after nega-
tive EGD and colonoscopy should undergo small-bowel
evaluation.
In the setting of IDA that exists with obscure GI
bleeding, there are numerous options to consider for further
evaluation. Radiographic techniques include barium stud-
ies, such as small-bowel follow-through and enteroclysis;
nuclear studies, such as tagged red blood cell scans and
Meckel’s scan; computed tomography (CT) and magnetic
resonance imaging with enteroclysis; and angiography.
Endoscopic techniques include repeating EGD and colon-
oscopy, push enteroscopy, double-balloon enteroscopy
(DBE), and WCE. Surgical procedures include exploratory
laparotomy with and without intraoperative enteroscopy
[53].
The most recent AGA technical review addressing
obscure GI bleeding in 2007 suggests that WCE is the
preferred method of small-bowel evaluation due to the
length of the small bowel examined, the quality of
the examination, and its non-invasiveness. The relative
utility of small-bowel follow-through and enteroclysis has
signiﬁcantly declined due to their lower diagnostic yield; at
present they are not indicated in the absence of signs of
small-bowel obstruction [55]. Similarly, tagged red blood
cell scans and angiography are of low yield unless the
patient is rapidly bleeding. In the setting of IDA, WCE is
diagnostically superior to small-bowel X-ray series and
push enteroscopy; WCE identiﬁes sources of bleeding in
the small bowel twice as frequently as does push enteros-
copy [55]. WCE has a higher diagnostic yield than does
DBE, although DBE remains useful in that it is often
complementary especially when performed after WCE
identiﬁes areas that require treatment or biopsy [1]. When
comparing WCE to the ‘gold standard’ of intraoperative
endoscopy, the calculated sensitivity was 95%, speciﬁcity
75%, and positive and negative predictive values were 95
and 86% respectively [53].
Major disadvantages of WCE include the inability to
perform biopsy or therapy and the risk of a retained cap-
sule, which may necessitate surgical exploration. Other
limitations include the inability to wash or repeatedly
examine lesions, the confounding effect of intraluminal
bile which can be mistaken for blood, and the current lack
of backing by insurance companies. WCE is generally
contraindicated in the presence of small intestinal stric-
tures/obstruction and pregnancy. Although thought to
interfere with implanted cardiac pacemakers, no reports to
date support this contention.
In patients with IDA, WCE identiﬁed small-bowel ero-
sions, ulcerations, and angiodysplasia most frequently.
Active bleeding in the small intestine without any
Table 3 Pathological conditions of the GI tract associated with iron deﬁciency (adapted and modiﬁed from [3, 4, 22])
Upper GI tract only Lower GI tract only Either or both
Gastric ulcer Colonic adenoma Crohn’s disease
Duodenal ulcer Colonic carcinoma Vascular ectasia
Gastric carcinoma Ulcerative colitis Portal hypertensive gastropathy or colopathy
Watermelon stomach Idiopathic cecal ulcer Parasitic infections (hookworm, whipworm, amebiasis, etc.)
Dieulafoy’s ulcer
Hiatal hernia Nonsteroidal anti- inﬂammatory drug gastropathy or enteropathy
Erosive esophagitis
Erosive gastritis
Celiac disease
Atrophic gastritis
Helicobacter pylori chronic gastritis
Gastric surgery
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123identiﬁable lesion was observed in 11% of patients, clas-
sifying this ﬁnding as a major causative factor for IDA with
or without signs of obscure GI bleeding [56]. The diag-
nostic yield for WCE increases with advancing age, likely
secondary to the increased use of NSAIDs, ASA, and
warfarin.
The etiologies of obscure GI bleeding that may cause
IDA vary with age. Likely sources in patients younger than
40 include small-intestinal tumors (i.e., lymphomas, carci-
noid tumors, adenocarcinomas, and polyps from hereditary
polyposis syndromes), Meckel’s diverticulum, Dieulafoy’s
lesion, and Crohn’s disease. Patients older than 40 are more
likely to have vascular lesions, which account for 40% of all
causes, and NSAID-induced small-intestinal disease. Less
common causes include hemobilia in patients who have
undergone liver biopsy, have been exposed to trauma, or
have hepatocellular cancer, hemosuccus pancreaticus in
patients with necrotizing pancreatitis or have undergone
pancreatic transplantation, and aortoenteric ﬁstula in
patients with prior abdominal aortic aneurysm repair [53].
Anemia in IBD patients is often secondary to a combi-
nation of IDA and ACD. The utility of performing upper
endoscopy in adult patients with IBD presumed to be dis-
tally conﬁned has not been studied, however pediatric data
suggests that it is useful in differentiating Crohn’s disease
from ulcerative colitis [57] and therefore may be helpful in
the investigation of IDA in adults with IBD as well.
In many patients, after appropriate GI evaluation is
performed, the cause of IDA is still not identiﬁed. As
previously mentioned, other explanations to consider
include non-GI blood loss, misdiagnosis of anemia type,
missed lesions and nutritional deﬁciency [4]. If patients do
not have signiﬁcant anemia or clinical symptoms, a rea-
sonable approach would be to follow patients clinically,
start iron treatment, and stop the use of any potentially
offending medications such as NSAIDs or ASA if possible.
Patients who do not respond to iron supplementation, have
severe anemia, or suspected serious illness, will likely
require continued GI evaluation including repeat endo-
scopic and serologic tests [1].
When to Get Help
There are no known guidelines for when to seek hemato-
logic referral for further evaluation of IDA. Nevertheless,
in the setting of continued IDA of unknown source that is
severe or refractory to treatment, or in anemia that appears
to be multifactorial, it is reasonable to seek assistance from
a hematologist. As previously mentioned, in addition to
IDA, other etiologies to consider in the differential diag-
nosis of microcytic, hypochromic anemias include ACD,
thalassemia, and sideroblastic anemia.
Treatment
Treatment of iron deﬁciency should begin with dietary
replacement (i.e., fortiﬁed cereals and breads, red meat,
beans, green leafy vegetables), but when diet alone is inad-
equate to restore iron stores and Hgb to normal levels, or
when anemia is severe, treatment with exogenous iron sup-
plements should be implemented. Treatment is dependent
on the urgency of the situation and the patient’s presenting
symptoms. If serum hemoglobin is\8 g/dl and the patient
is symptomaticwith shortnessofbreath,extremefatigue,or
signs of myocardial ischemia, then an immediate blood
transfusion is warranted. When the patient is asymptomatic
and the hemoglobin level is within an acceptable range,
treatment should begin with oral iron.
Oral Iron
As the ﬁrst-line treatment for IDA, oral iron is safe, cost-
effective, and convenient. Ferrous sulfate and ferrous glu-
conate are the two preferred oral preparations of iron,
given the low cost and good bioavailability of elemental
iron. To optimize iron absorption, ferrous salts should be
taken with orange juice, since iron is better absorbed in an
acidic environment. Furthermore, ascorbic acid reduces the
oxidation of ferrous to ferric iron. Foods that reduce iron
absorption include tea, coffee, phosphate-containing car-
bonated beverages, and medications that block gastric acid
secretion (i.e., antacids, H2 blockers, proton pump inhibi-
tors). Ferrous sulfate is typically taken in 300-mg tablets
(60 mg elemental iron); ferrous gluconate is taken in 320-
mg tablets (36 mg elemental iron) three to four times daily.
Common adverse effects of oral iron supplements include
nausea, epigastric discomfort, and constipation, all of
which are dose-related. Adverse effects can occur in up to
20% of patients, impairing compliance [10]. Since the
duodenum can maximally absorb 10–20 mg of iron
daily,[90% of ingested iron is not absorbed, where it can
produce erosions and enteric siderosis [58, 59]. Successful
iron repletion is possible with lower doses such as 15 mg
elemental iron/day [60–62]. Enteric-coated iron tablets are
better tolerated but are less effective because the iron may
not be released in the duodenum, where it is primarily
absorbed [10, 11]. The therapeutic goal of oral iron therapy
is to induce reticulocytosis within days and raise serum
hemoglobin by 1–2 g/dl every 2 weeks, ultimately restor-
ing iron stores in approximately 3–4 months [3, 12]. In
light of the foregoing considerations, decreasing the dose
of oral iron preparations if adverse effects develop should
be tried; if reticulocytes or RDW increase within 4 weeks,
the dose is probably adequate.
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Indications
When the patient fails oral iron therapy, parenteral iron
therapy is indicated [63]. Indications for parenteral iron
therapy in GI disease include: (1) high iron requirements
due to chronic uncorrectable bleeding or chronic hemodi-
alysis; (2) iron malabsorption secondary to a GI condition
(i.e., celiac disease, atrophic gastritis, gastric bypass); (3)
IBD with ineffective erythropoiesis, poor absorption, and
intolerance (also see below); (4) severe anemia with
unwillingness to receive transfusions; (5) intolerance of or
noncompliance with oral therapy; (6) need for rapid resti-
tution of iron stores (e.g., pre-operative) [2, 3, 64, 65],
although some suggest that in the case of celiac disease,
institution of a gluten-free diet is curative over 6–12
months [66], and (7) possibly in restless legs and related
syndromes [27]. Note that parenteral iron sucrose therapy
is currently restricted by the US FDA to renal failure
patients either undergoing dialysis or pre-dialysis who are
receiving concurrent epoeitin therapy.
Preparations
Intravenous iron preparations are available as ferric glu-
conate, iron sucrose, iron dextran, and ferric carboxymal-
tose. Ferric gluconate (Ferrlecit) is effective in treating
IDA patients on hemodialysis and IDA patients without
renal disease [3]. For those who develop hypersensitivity
reactions to ferric gluconate, iron sucrose (Venofer) may
be given [3, 67]. Doses of iron sucrose for patients on
hemodialysis are adjusted lower [67]. Also, iron sucrose
appears to be a safe and effective alternative form of
treatment that is able to rapidly restore iron stores in
pregnant and postpartum women with IDA [68–70]. Iron
dextran (INFeD, DexFerrum), unlike ferric gluconate and
iron sucrose, is higher in molecular weight and releases
iron more slowly to be bound by transferrin and to supply
the bone marrow. Because of these properties, it has his-
torically had the advantage of being able to be adminis-
tered in large doses (200–500 mg), satisfying the patient’s
total iron requirement with just one administration (total-
dose infusion), thereby saving cost and improving patient
compliance. Nevertheless, a smaller test dose is currently
recommended due to reports of severe anaphylactic reac-
tions in addition to adverse effects such as hypoten-
sion, myalgia, arthralgia, nausea, vomiting, and fever.
Therefore, iron dextran is rarely used as it is contraindi-
cated in the pediatric population and discouraged in adults
[71]. A newly suggested alternative to total-dose iron
dextran administration may be giving total-dose or high-
dose iron sucrose infusions that are equally effective and
associated with fewer toxicities [72–74].
Ferric carboxymaltose (Ferinject R) is a novel intrave-
nous iron preparation that can be administered in high
single doses (of up to 1,000 mg iron per week) on a weekly
basis at infusions rates much higher than for iron sucrose.
To date, phase III studies support its safety and efﬁcacy in
diverse patient populations, including IBD patients with
iron deﬁciency anemia [75].
Considerations for IBD Patients
Anemia in IBD has received particular attention due to the
importance of the disease combined with its high preva-
lence of anemia [76]; routine monitoring with complete
blood counts is an integral part of management that is often
overlooked. Correcting anemia improves the quality of life
in anemic patients, with normalization of hemoglobin and
ferritin being the treatment goals.
The efﬁcacy of oral iron therapy in IBD patients may be
hindered by gastrointestinal side-effects, reduced absorp-
tion in the setting of inﬂammation, and altered distribution.
Also, due to the presence of pre-existing mucosal injury,
unabsorbed luminal iron, perhaps due to its strong oxidiz-
ing properties, may exacerbate the inﬂammatory lesions of
IBD, whereas intravenous iron therapy may suppress
inﬂammation in Crohn’s disease [58, 59, 77–80]. In a
controlled trial, the dose of oral iron was either reduced or
discontinued in 52% of subjects due to gastrointestinal
effects [81], although oral ferrous sulfate was well tolerated
and as effective as intravenous iron after 12 weeks in
another trial [75]. Given the efﬁcacy and toleration of
intravenous iron in IBD, and the impaired quality of life
and cognitive function in anemic patients with IBD [82],
the use of intravenous iron in anemic patients with IBD
with either severe anemia (Hgb\10), or intolerance or
non-response to oral iron [77] has been advocated; an IBD
working group recommended IV iron therapy for all IBD
patients with IDA [83]. Please also refer to a separate
recent review of this area [84].
Recombinant Human Erythropoietin
Recombinant human erythropoietin (EPO) is most com-
monly used for and FDA indicated for the treatment of
ACD in patients with chronic renal failure. These
patients are supplemented with IV iron in order to
compensate for the functional iron deﬁciency that is
caused by increased erythropoiesis [85]. In the setting of
GI-related IDA, however, EPO may be indicated in
several situations. In patients with GI cancer where IDA
is common, inappropriate low levels of endogenous
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123erythropoietin may also be present [86]. Therefore, giv-
ing cancer patients EPO together with IV iron supple-
mentation for at least 14 days before an operation
reduces the need for perioperative autologous blood
transfusions [86, 87]. The synergistic effect of the com-
bination therapy, however, appears to be limited to IV
rather than oral iron preparations [86, 87].
Patients with IBD also have faster and larger hemoglo-
bin increases when they are concomitantly started on EPO
once restoration of their iron stores is achieved [2].
Erythropoiesis is decreased from IBD-associated inﬂam-
mation as well as from some of the anti-inﬂammatory
treatments of IBD. Erythropoietin therapy should be used
for IBD patients who are unresponsive to intravenous iron
and always used in combination with intravenous iron
replacement [77, 83]. Since many gastroenterologists are
unfamiliar with the use of EPO, we recommend that the
drug be given, at least initially, under the supervision of a
hematologist or nephrologist experienced in its use. This
subject has also been reviewed separately [88].
In addition to iron replacement with or without EPO,
patients should be managed according to the spe-
ciﬁc underlying cause of IDA. Mass lesions in the GI tract
may require surgical intervention, whereas disorders such
as gastritis, peptic ulcers, or IBD may be managed medi-
cally [4]. Vascular ectasias may be endoscopically man-
aged via thermal-based treatment or medically managed
via hormonal compounds or octreotide (Table 4)[ 4].
Summary and Conclusions
Occult GI bleeding remains the most common cause of
IDA in the adult male and postmenopausal female popu-
lations. Trends of laboratory indices and the serum ferritin,
especially when a higher upper limit of normal is used, are
extremely helpful in the diagnosis of IDA. When the
diagnosis of IDA has been established, the clinician should
proceed to upper and lower GI endoscopy in most cases.
When a source is not found after routine endoscopy, further
diagnostic workup includes repeat testing and evaluation of
the small bowel often using WCE. Treatment of IDA
should be aimed speciﬁcally at the underlying cause. If the
patient requires iron replacement, oral therapy should be
initiated as the ﬁrst-line therapy; dose reduction is sug-
gested in iron-intolerant subjects. When the patient fails
oral therapy, or if oral therapy is contraindicated or dis-
couraged, parenteral therapy should be instituted. Cur-
rently, the preferred choice for intravenous iron therapy is
iron sucrose due to favorable pharmacologic properties
combined with low rates of adverse drug events.
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